

Therapeutic Effect of **Evenamide**, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial.

Anand R, Turolla A, Chinellato G, Roy A, Hartman RD.

Int J Neuropsychopharmacol. 2024 Dec 28;28(1):pyae061

(Study 015)

Efficacy and safety of **evenamide**, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.

Anand R, Turolla A, Chinellato G, Sansi F, Roy A, Hartman R.

Neuropharmacology. 2024 Dec 19;266:110275

(Study 008A)